IntraBio Inc. has begun enrolment in its pivotal Phase III IB1001-304 study of levacetylleucine for people with genetically confirmed CACNA1A-related disorders, moving the investigational indication into what could become the decisive efficacy test for a patient population without an approved disease-specific therapy. The company said on August 19 that it expects recruitment to exceed the study target and finish in October 2026, with the core trial designed to run for approximately six months.
The development is notable for more than its recruitment timetable. IB1001-304 is described by IntraBio as the first pivotal clinical trial conducted specifically in CACNA1A-related disorders, and it extends a clinical-development strategy already used for levacetylleucine in Niemann-Pick disease type C and ataxia-telangiectasia. Levacetylleucine is already approved in the United States and European Union for defined neurological manifestations of Niemann-Pick disease type C, but it remains investigational for CACNA1A-related disorders.
The distinction matters because regulatory experience with the same molecule cannot substitute for efficacy evidence in a different genetic neurological disorder. IntraBio has gained useful information about dosing, manufacturing, exposure and tolerability from its existing programme, but IB1001-304 still has to show that levacetylleucine produces a clinically interpretable benefit against placebo in the CACNA1A population that the company ultimately hopes to treat.
Why could rapid recruitment become more than an operational milestone for the CACNA1A Phase III programme?
The public clinical-trial record lists an estimated enrolment of 60 participants aged four years and older, using a multinational, randomised crossover design. IntraBio now expects the study to exceed that target, although it has not disclosed how many patients have already entered the trial or how far beyond 60 participants recruitment may ultimately run. The company said sites are operating across Austria, Germany, Greece, Italy, Switzerland, the United Kingdom and the United States.
That recruitment expectation is particularly interesting because rare-disease trials frequently face the opposite problem. Small geographically dispersed populations, molecular-diagnosis requirements and competition for eligible participants can slow enrolment enough to become a major development risk. CACNA1A-related disorders are genetically defined, which gives investigators a relatively objective entry criterion, but their manifestations can span different neurological phenotypes and ages.
IntraBio’s confidence may partly reflect its recent experience in ataxia-telangiectasia. Its Phase III IB1001-303 study enrolled 73 participants after originally targeting a substantially smaller population, with the company reporting that recruitment was completed in seven weeks after strong patient-community interest. That history does not guarantee the same outcome in CACNA1A disorders, but it provides some operational basis for management’s expectation that IB1001-304 could also over-enrol.
Additional enrolment could have analytical value as well as logistical significance. In small rare-disease trials, a handful of participants with unusual baseline characteristics or highly variable symptom trajectories can materially affect results. A larger sample does not eliminate heterogeneity, but it can improve the amount of information available to estimate treatment effects and examine whether findings are consistent across clinically different participants.
How does the IB1001-304 crossover design try to manage a highly heterogeneous genetic disorder?
Participants in IB1001-304 are expected to complete an approximately two-week baseline period before being randomised to levacetylleucine or placebo for about 12 weeks. They then cross over to the opposite treatment for another approximately 12 weeks, meaning each participant serves, in part, as his or her own comparator. The registered primary outcome is based on the Scale for the Assessment and Rating of Ataxia, or SARA, comparing assessments at the ends of the two treatment periods.
That design has obvious appeal in a genetically defined disorder with substantial person-to-person variation. CACNA1A pathogenic variants are associated with a spectrum that includes episodic ataxia type 2, spinocerebellar ataxia type 6, familial hemiplegic migraine and other neurological presentations. GeneReviews notes that CACNA1A-associated phenotypes can include episodic or progressive ataxia, cerebellar manifestations, migraine and developmental or epileptic encephalopathy.
A crossover trial can reduce some of the noise produced by comparisons between people whose baseline neurological function differs considerably. Instead of relying only on whether one randomised group happens to be more impaired than another, investigators obtain active-treatment and placebo observations from the same participants.
The trade-off is that crossover trials require particularly careful handling of period effects and potential carryover. If a treatment produces an effect that persists into the subsequent placebo period, the second half of the study can become harder to interpret. The statistical analysis therefore needs to show that the treatment signal is robust to the structure of the crossover rather than merely benefiting from it.
CACNA1A heterogeneity creates another question. A therapy could produce a measurable improvement in ataxia while having less influence on other manifestations associated with particular CACNA1A variants. The primary endpoint may therefore be well suited to the motor phenotype the study is designed to measure without necessarily capturing every clinically important dimension of the broader disorder spectrum.
What does levacetylleucine’s Niemann-Pick disease approval actually tell us about this Phase III study?
Levacetylleucine enters IB1001-304 with considerably more human development history than a first-in-class molecule entering its first pivotal study. The United States Food and Drug Administration approved AQNEURSA, IntraBio’s levacetylleucine product, in September 2024 for neurological manifestations of Niemann-Pick disease type C in adults and paediatric patients weighing at least 15 kilograms. The European Union subsequently authorised the medicine for neurological manifestations of Niemann-Pick disease type C in adults and children aged six years and older weighing at least 20 kilograms, either with miglustat or alone when miglustat is not tolerated.
The FDA’s pivotal evidence came from a 60-patient randomised, double-blind, placebo-controlled, two-period crossover trial lasting 24 weeks. Participants received levacetylleucine or placebo for 12 weeks before crossing directly to the other treatment, with a modified functional version of SARA serving as the primary efficacy endpoint.
That regulatory precedent explains why IntraBio is carrying a familiar architecture into IB1001-304. The company is not asking regulators to evaluate an entirely novel trial concept for levacetylleucine.
Yet the NPC approval should not be interpreted as evidence that the drug will work in CACNA1A-related disorders. Niemann-Pick disease type C and CACNA1A disorders have different underlying biology and clinical trajectories. The earlier programme principally reduces development uncertainty around the molecule and the trial framework. It does not remove indication-specific efficacy risk.
Does the positive ataxia-telangiectasia Phase III study strengthen the rationale for using SARA again?
A second piece of evidence may be more directly relevant to the endpoint strategy. IntraBio recently completed another randomised, double-blind crossover Phase III trial, IB1001-303, in ataxia-telangiectasia, a neurological disorder in which ataxia is central to the clinical presentation.
The peer-reviewed Phase III study enrolled 73 participants aged four years and older. Levacetylleucine was associated with a mean 1.92-point reduction in SARA score compared with a 0.14-point reduction with placebo, producing an estimated treatment effect of 1.88 points in favour of levacetylleucine. The difference was statistically significant, and secondary measures including the International Cooperative Ataxia Rating Scale and investigator-rated Clinical Global Impression also favoured treatment.
Those results have already moved beyond an academic exercise. The United States Food and Drug Administration accepted IntraBio’s supplemental New Drug Application seeking an ataxia-telangiectasia indication and granted Priority Review, with a target action date of September 19, 2026. Priority Review does not indicate that approval is likely, but it means another levacetylleucine programme using a related pivotal strategy is now undergoing regulatory evaluation.
For the CACNA1A programme, the A-T data strengthen the argument that SARA can detect a treatment-associated change during a 12-week period in at least one other inherited neurological condition. They still do not establish what magnitude of SARA change should be expected, or considered clinically meaningful, in a mixed CACNA1A population.
That distinction will become important when IB1001-304 eventually reads out. Statistical significance alone will not settle the clinical question. Regulators and neurologists will want to understand the size of the effect, consistency between treatment periods, distribution of responses and whether changes translate into observable improvements in functions that matter to patients.
Why could patient selection become the most important variable once recruitment closes?
The umbrella term CACNA1A-related disorders hides substantial clinical complexity. The CACNA1A gene encodes a component of neuronal P/Q-type voltage-gated calcium channels, and pathogenic alterations can produce phenotypes ranging from episodic ataxia and progressive cerebellar dysfunction to hemiplegic migraine and neurodevelopmental or epileptic syndromes. Even members of the same family carrying CACNA1A variants can display different combinations of ataxia and migraine manifestations.
That makes the composition of the final Phase III population potentially as important as the headline enrolment number. If the study recruits well beyond 60 patients but the population contains markedly different baseline manifestations, investigators will need to demonstrate that the aggregate endpoint remains interpretable and that the trial is not being driven disproportionately by one phenotype or subgroup.
Conversely, the genetic confirmation requirement gives IB1001-304 an important advantage. The study is not grouping patients solely on the basis of nonspecific neurological symptoms. It is testing treatment in individuals linked by pathogenic CACNA1A alterations, allowing the programme to ask whether a single therapeutic approach can influence a measurable neurological manifestation across that molecularly defined spectrum.
If successful, that could support a broader indication than a study confined to one narrowly defined CACNA1A phenotype. If responses vary substantially, however, the eventual regulatory and development strategy could require greater attention to phenotype, variant class or baseline manifestation.
What should matter after IntraBio reaches its expected October recruitment finish line?
Completing recruitment in October would remove one of the most visible execution risks surrounding IB1001-304, particularly if IntraBio exceeds its original 60-patient target. It would not yet provide evidence that levacetylleucine benefits people with CACNA1A-related disorders.
The next meaningful questions will concern the actual number and composition of enrolled participants, retention through both crossover periods, the primary SARA result, consistency of effect and the safety experience within this specific population. Any open-label extension may add longer-term information, but the randomised placebo-controlled portion remains the critical test of efficacy.
There is also an unusual amount happening around levacetylleucine outside the CACNA1A study. AQNEURSA already has regulatory approval for Niemann-Pick disease type C in major markets, and the United States regulatory decision on the proposed ataxia-telangiectasia indication is scheduled before IntraBio expects CACNA1A recruitment to close. Consequently, the company could enter the later stages of IB1001-304 with either an expanded regulatory precedent for levacetylleucine or a new set of questions arising from the FDA’s ataxia-telangiectasia decision.
For now, the August enrolment announcement is best viewed as an execution milestone rather than a clinical result. The more consequential proposition is that IntraBio is attempting to extend a molecule with established regulatory history and two previous pivotal crossover programmes into a genetically complex neurological population that still lacks an approved targeted therapy. If recruitment does close in October as expected, attention will quickly move away from whether the company can find enough patients and toward the much harder question: whether levacetylleucine can produce a convincing, clinically meaningful and regulatorily usable effect across the CACNA1A spectrum.
